Edition:
United States

CytoDyn Inc (CYDY.PK)

CYDY.PK on OTC Markets Group

0.64USD
24 Mar 2017
Change (% chg)

$-0.01 (-1.54%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.65
Day's Low
$0.62
Volume
39,780
Avg. Vol
276,244
52-wk High
$1.57
52-wk Low
$0.57

Latest Key Developments (Source: Significant Developments)

CytoDyn files for mixed shelf of up to $100 million
Friday, 26 Aug 2016 05:09pm EDT 

CytoDyn Inc :Files for mixed shelf of up to $100 million - SEC filing.  Full Article

FDA clears CytoDyn for relaxed entry criteria for its ongoing phase 3 trial in HIV-Infected Patients
Monday, 21 Dec 2015 04:01pm EST 

CytoDyn:Says the FDA has allowed a significant change to the entry criteria for patients in the Company's ongoing PRO 140 Phase 3 trial.This change allows the Company to enroll patients with resistance to a single antiretroviral drug, significantly expanding the number of patients available for the study.  Full Article

CytoDyn cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV
Tuesday, 9 Jun 2015 06:29am EDT 

CytoDyn Inc:Says it has initiated its first Phase 3 study for PRO 140, the company's self-injectable antibody for the treatment of HIV.Company's Phase 3 protocol provides for a 25-week study with 300 HIV-positive patients.  Full Article

More From Around the Web

BRIEF-CytoDyn updates on Pro 140 late-stage trial

* CytoDyn files protocol for extended access to PRO 140 for patients who reach the end of PRO 140 pivotal phase 3 trial